)
Overview
<ul>
<li>Health and wellness firm’s Q2 revenue fell 27.8%, missing analyst expectations</li>
<li>Adjusted EPS for Q2 was $0.15, down from $0.22 a year ago</li>
<li>Company announced a new $60 mln share repurchase program</li>
</ul>
Outlook
<ul>
<li>LifeVantage expects fiscal 2026 revenue between $185 mln and $200 mln</li>
<li>Company forecasts adjusted EBITDA of $15 mln to $19 mln for fiscal 2026</li>
<li>LifeVantage projects adjusted EPS of $0.60 to $0.80 for fiscal 2026</li>
</ul>
Result Drivers
<ul>
<li>GLP-1 SYSTEM CHALLENGES - Revenue decline driven by decreased sales of MindBody GLP-1 System as company cycled its launch</li>
<li>LOVEBIOME OFFSET - Sales of LoveBiome product line partially offset revenue decline, acquired in October 2025</li>
</ul>
Key Details
Metric Beat/Mis Actual Consensu
s s
Estimate
Q2 Miss $48.93 $54.39
Revenue mln mln (3
Analysts
)
<h3>Q2 EPS $0.02</h3>
Q2 Net $276,000
Income
Q2 Gross $36.21
Profit mln
<h3>Q2 $35.72</h3>
Operatin mln
g
Expenses
<h3>Q2 $487,000</h3>
Operatin
g Income
<h3>Q2 $473,000</h3>
Pretax
Profit
Analyst Coverage
<ul>
<li>The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 2 “strong buy” or “buy”, no “hold” and no “sell” or “strong sell”</li>
<li>The average consensus recommendation for the pharmaceuticals peer group is “buy”</li>
<li>Wall Street’s median 12-month price target for LifeVantage Corp is $14.50, about 170.5% above its February 3 closing price of $5.36</li>
<li>The stock recently traded at 5 times the next 12-month earnings vs. a P/E of 8 three months ago</li>
</ul>
Press Release: For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

LifeVantage Q2 revenue falls 27.8%, misses estimates